JPS615787A - 昆虫細胞内でのポリペプチド類の産生 - Google Patents

昆虫細胞内でのポリペプチド類の産生

Info

Publication number
JPS615787A
JPS615787A JP60017702A JP1770285A JPS615787A JP S615787 A JPS615787 A JP S615787A JP 60017702 A JP60017702 A JP 60017702A JP 1770285 A JP1770285 A JP 1770285A JP S615787 A JPS615787 A JP S615787A
Authority
JP
Japan
Prior art keywords
promoter
virus
gene product
vector
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP60017702A
Other languages
English (en)
Japanese (ja)
Inventor
ロイス・ケイ・ミラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idaho Research Foundation Inc
Original Assignee
Idaho Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24300383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS615787(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idaho Research Foundation Inc filed Critical Idaho Research Foundation Inc
Publication of JPS615787A publication Critical patent/JPS615787A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
JP60017702A 1984-01-31 1985-01-31 昆虫細胞内でのポリペプチド類の産生 Pending JPS615787A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57545384A 1984-01-31 1984-01-31
US575453 1984-01-31

Publications (1)

Publication Number Publication Date
JPS615787A true JPS615787A (ja) 1986-01-11

Family

ID=24300383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60017702A Pending JPS615787A (ja) 1984-01-31 1985-01-31 昆虫細胞内でのポリペプチド類の産生

Country Status (9)

Country Link
EP (1) EP0155476A1 (enExample)
JP (1) JPS615787A (enExample)
KR (1) KR850005499A (enExample)
AU (1) AU3824285A (enExample)
DK (1) DK518384A (enExample)
ES (1) ES8604308A1 (enExample)
GR (1) GR850265B (enExample)
IL (1) IL73942A0 (enExample)
ZA (1) ZA848495B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01285198A (ja) * 1988-05-12 1989-11-16 Zenji Matsuura 日本脳炎ウイルス表面抗原蛋白質の製造法
JPH0221955A (ja) * 1988-07-07 1990-01-24 Nippon Steel Corp 流体噴射ノズル
JPH03500602A (ja) * 1987-07-24 1991-02-14 カイロン　コーポレーション 昆虫細胞の増殖およびそれによる生産物の発現のための無血清培地

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879236A (en) * 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
JPS619288A (ja) * 1984-06-21 1986-01-16 Dai Ichi Seiyaku Co Ltd ペプチド類の製法
IL80529A0 (en) * 1985-11-14 1987-02-27 Daiichi Seiyaku Co Method of producing peptides
IE60285B1 (en) * 1985-12-18 1994-06-29 Microgenesys Inc Method for producing selected polypeptides in virally infected insect cells and polypeptides isolated therefrom
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
GR871029B (en) 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
NZ221702A (en) * 1986-09-08 1989-02-24 Bishop David H L Expression of human hepatitis b antigens in insects and cultured insect cells using recombinant baculoviruses
ES2008204A6 (es) * 1986-09-09 1989-07-16 Genetics Inst Metodos para producir cuerpos de inclusion polihedrica de composicion mezclada (pib),para coinfectar insectos huespedes y para producir proteinas heterologas en insectos.
US5071748A (en) * 1986-09-09 1991-12-10 Genetics Institute, Inc. Mixed baculovirus compositions and uses thereof
US5041379A (en) * 1987-03-16 1991-08-20 American Biogenetic Science, Inc. Heliothis expression systems
US5578468A (en) * 1987-08-10 1996-11-26 Duke University Site-specific RNA cleavage
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
GB8810808D0 (en) * 1988-05-06 1988-06-08 Wellcome Found Vectors
SE8802939D0 (sv) * 1988-08-19 1988-08-19 Kabigen Ab A method for the production and isolation of a fusion protein in eukaryotic cells
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
AU4647889A (en) * 1988-11-18 1990-06-12 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
US5244805A (en) * 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
EP0698094B1 (en) 1993-05-12 2004-02-04 Genetics Institute, LLC Bmp-11 compositions
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
EP0733109B9 (en) 1993-12-07 2006-07-05 Genetics Institute, LLC Bmp-12, bmp-13 and tendon-inducing compositions thereof
AU1377395A (en) * 1993-12-23 1995-07-10 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6165748A (en) 1997-07-11 2000-12-26 Genetics Institute, Inc. Frazzled nucleotide sequences and expression products
DE69840508D1 (de) 1997-08-27 2009-03-12 Childrens Hosp Medical Center Molekular-mimetika von meningokokkus b epitopen
BR9813930A (pt) 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
ATE446368T1 (de) 1998-01-14 2009-11-15 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
DK1141331T3 (da) 1998-12-16 2009-01-05 Novartis Vaccines & Diagnostic Human cyclinafhængig kinase (hPNQALRE)
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
AU783767B2 (en) 1999-10-14 2005-12-01 Takara Bio Usa, Inc. Anthozoa derived chromophores/fluorophores and methods for using the same
EP1223990B1 (en) 1999-10-15 2004-07-28 Genetics Institute, LLC Formulations of hyaluronic acid for delivery of osteogenic proteins
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
EP1985701B1 (en) 2000-01-10 2012-05-30 Novartis Vaccines and Diagnostics, Inc. Genes differentially expressed in breast cancer
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
US6689599B1 (en) 2000-10-20 2004-02-10 Genetics Institute, Llc Aggrecanase molecules
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
US7226587B2 (en) 2001-06-01 2007-06-05 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
WO2003012038A2 (en) 2001-07-27 2003-02-13 Wyeth Aggrecanase molecules
ES2386386T3 (es) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
WO2003054158A2 (en) 2001-12-19 2003-07-03 The University Of Chicago Rapidly maturing fluorescent proteins and methods for using the same
JP2005515779A (ja) 2002-01-31 2005-06-02 ワイス アグレカナーゼ分子
JP2005516614A (ja) 2002-02-05 2005-06-09 ワイス 切断アグレカナーゼ分子
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
AU2003243316A1 (en) 2002-05-24 2003-12-12 Nps Allelix Corp. Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
AU2003239865A1 (en) 2002-05-24 2003-12-12 Restoragen Inc. Method for universal enzymatic production of bioactive peptides
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
TW200518767A (en) 2003-09-12 2005-06-16 Wyeth Corp Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
US7829307B2 (en) 2003-11-21 2010-11-09 Nps Pharmaceuticals, Inc. Production of glucagon-like peptide 2
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
KR101222281B1 (ko) 2004-03-29 2013-01-28 가르파마 컴퍼니 리미티드 신규 갈렉틴 9 개변체 단백질 및 그 용도
EP1732944B1 (en) 2004-04-07 2012-09-05 The University of Chicago Monomeric red fluorescent proteins
EP1771205B1 (en) 2004-06-18 2016-10-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
JP2008507280A (ja) 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
NZ555308A (en) 2004-12-22 2010-10-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
PL1865940T3 (pl) 2005-03-21 2013-06-28 Virobay Inc Alfa-ketoamidowe związki jako inhibitory proteaz cysteinowych
EP3683230A1 (en) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
WO2007053732A2 (en) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
EP1951890A4 (en) 2005-11-16 2009-06-24 Ambrx Inc PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
KR20090060294A (ko) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
US7858759B2 (en) 2007-10-04 2010-12-28 Zymogenetics, Inc. Anti-zB7H6 antibody-drug conjugates
US8679749B2 (en) 2007-11-01 2014-03-25 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
CA2703830A1 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
US8003325B2 (en) 2007-11-30 2011-08-23 Mayo Foundation For Medical Education And Research Polymorphisms of the BLyS gene and use in diagnostic methods
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
PE20110480A1 (es) 2008-09-26 2011-07-01 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
EP2292781A1 (en) 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
EP2333074A1 (en) 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
PE20140160A1 (es) 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
WO2013014294A2 (en) 2011-07-27 2013-01-31 Genethon Improved baculovirus expression systems
ES2813698T3 (es) 2013-09-12 2021-03-24 Biomarin Pharm Inc Vectores de AAV que comprenden un gen que codifica el factor VIII
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
JP2018535929A (ja) 2015-09-24 2018-12-06 バイオマリン ファーマシューティカル インコーポレイテッド アデノ随伴ウイルス第ｖｉｉｉ因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤
TN2018000163A1 (en) 2015-11-12 2019-10-04 Res Inst Nationwide Childrens Hospital Methods of treating muscular dystrophy
CN108463211B (zh) 2015-11-16 2022-09-27 全国儿童医院研究所 用于治疗肌联蛋白类肌病和其它肌联蛋白病变的材料和方法
JP6994018B2 (ja) 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US20200231986A1 (en) 2017-09-29 2020-07-23 Massachusetts Eye And Ear Infirmary Production of adeno-associated viruses in insect cells
AU2019216257B2 (en) 2018-01-31 2025-11-20 Research Institute At Nationwide Children's Hospital Gene therapy for limb-girdle muscular dystrophy type 2C
KR20210008501A (ko) 2018-05-09 2021-01-22 바이오마린 파머수티컬 인크. 페닐케톤뇨증을 치료하는 방법
CN112424345A (zh) 2018-05-14 2021-02-26 生物马林药物股份有限公司 Aav载体在青少年对象中的稳定表达
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
IL279789B2 (en) 2018-06-29 2026-04-01 Res Inst Nationwide Childrens Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2A
KR20210133242A (ko) 2019-02-26 2021-11-05 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 B-사르코글리칸의 아데노 관련 바이러스 벡터 전달 및 근이영양증의 치료
WO2020232044A1 (en) 2019-05-14 2020-11-19 Biomarin Pharmaceutical Inc. Methods of redosing gene therapy vectors
CA3150964A1 (en) 2019-08-21 2021-02-25 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
CA3153782A1 (en) 2019-09-27 2022-03-08 Biomarin Pharmaceutical Inc. Characterization of gene therapy viral particles using size exclusion chromatography and multi-angle light scattering technologies
US20230340078A1 (en) 2019-11-14 2023-10-26 Biomarin Pharmaceutical Inc. Treatment of hereditary angioedema with liver-specific gene therapy vectors
EP4103699A1 (en) 2020-02-10 2022-12-21 BioMarin Pharmaceutical Inc. Virus-free cell cultures
WO2021183895A1 (en) 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用ａａｖ及治療調配物之苯酮尿症治療
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
KR20230078805A (ko) 2020-11-02 2023-06-02 바이오마린 파머수티컬 인크. 아데노-연관 바이러스의 농축 공정
TW202332472A (zh) 2021-10-01 2023-08-16 美商拜奧馬林製藥公司 利用ａａｖ基因療法載體進行之遺傳性血管水腫治療及治療性調配物
US12285497B2 (en) 2021-10-15 2025-04-29 Research Institute At Nationwide Children's Hospital Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
UY40442A (es) 2022-09-22 2024-02-15 Biomarin Pharm Inc Tratamiento de la miocardiopatía arritmogénica con vectores de genoterapia con aav
UY40443A (es) 2022-09-22 2024-02-15 Biomarin Pharm Inc Tratamiento de la miocardiopatía con vectores de genoterapia con aav
TW202444398A (zh) 2023-01-09 2024-11-16 美商拜奧馬林製藥公司 表觀遺傳修飾劑改善aav基因療法之耐久性
WO2024238591A2 (en) 2023-05-15 2024-11-21 Biomarin Pharmaceutical Inc. Methods of treating anti-aav seropositive hemophilia patients
WO2025214477A1 (en) 2024-04-12 2025-10-16 Skyline Therapeutics (Shanghai) Co., Ltd. Treatment of genetic cardiomyopathies with aav gene therapy vectors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03500602A (ja) * 1987-07-24 1991-02-14 カイロン　コーポレーション 昆虫細胞の増殖およびそれによる生産物の発現のための無血清培地
JPH01285198A (ja) * 1988-05-12 1989-11-16 Zenji Matsuura 日本脳炎ウイルス表面抗原蛋白質の製造法
JPH0221955A (ja) * 1988-07-07 1990-01-24 Nippon Steel Corp 流体噴射ノズル

Also Published As

Publication number Publication date
AU3824285A (en) 1985-08-08
ES8604308A1 (es) 1986-01-16
DK518384D0 (da) 1984-10-31
IL73942A0 (en) 1985-03-31
GR850265B (enExample) 1985-05-27
DK518384A (da) 1985-07-01
ZA848495B (en) 1985-09-25
EP0155476A1 (en) 1985-09-25
ES537766A0 (es) 1986-01-16
KR850005499A (ko) 1985-08-26

Similar Documents

Publication Publication Date Title
EP0155476A1 (en) Production of polypeptides in insect cells
US5348886A (en) Method of producing recombinant eukaryotic viruses in bacteria
US5753220A (en) Cysteine protease gene defective baculovirus, process for its production, and process for the production of economic protein by using the same
US5004687A (en) Insect virus vector with broadened host range
JP5986381B2 (ja) ベクター
JP2000300254A (ja) 寄生体由来抵抗性
Yang et al. Improving baculovirus infectivity by efficiently embedding enhancing factors into occlusion bodies
WO1997043403A1 (en) Baculovirus cloning system
EP0397485A1 (en) Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
JP2011519263A (ja) レシピエント宿主細胞におけるゲノム組込み方法
CN118048284A (zh) 铜绿假单胞菌fur基因缺失突变株及其构建方法和应用
Noad et al. Multigene expression of protein complexes by iterative modification of genomic Bacmid DNA
CN102286534B (zh) 表达多外源基因的昆虫生物反应器及其构建方法和应用
CN101372684A (zh) 一种简便高效构建重组杆状病毒的方法
Xiang et al. The Bombyx mori nucleopolyhedrovirus (BmNPV) ODV-E56 envelope protein is also a per os infectivity factor
Byrd et al. Construction of recombinant vaccinia virus: cloning into the thymidine kinase locus
JPH06507545A (ja) 組み換えハイブリッドポーリンエピトープ
JP2693948B2 (ja) 侵入性微生物
JPS62503074A (ja) 不安定な遺伝性レプリコンの安定化方法
IE60285B1 (en) Method for producing selected polypeptides in virally infected insect cells and polypeptides isolated therefrom
MXPA04008753A (es) Baculovirus disenados y su uso.
CN116676274B (zh) 可自失活噬菌体及其制备方法和应用
Yao et al. A highly efficient method for the generation of a recombinant Bombyx mori nuclear‐polyhedrosis‐virus Bacmid and large‐scale expression of foreign proteins in silkworm (B. mori) larvae
Atkinson et al. Baculoviruses as vectors for foreign gene expression in insect cells
WO1998050571A1 (en) Entomopoxvirus-based gene delivery vector for vertebrates